PubMed HealthSearch

PubMed · 3251962

[Cell sorting in flow cytometry].

Abstract

The aim of the presentation is to introduce a dramatic accomplishments of high technology and the current applications of medicine, particularly in the field of Gynecology and Obstetrics. An author's demonstration includes both of a brief basic concept of window and fraction sorting and some clinical applications. Cell sorting based on genotypic (neoplastic) and phenotypic markers of a benign and malignant lesions of female genital tract seems to be expressed at the cellular and molecular level in terms of degree of cell growth, differentiation and functions, which are not readily appreciated by descriptive morphology. DNA aneuploidy is a conclusive marker of malignant characteristics and a monoclonal antibodies of Bromodeoxyuridine (BrdU), an analog of thymidine, is an available identification of DNA synthetic cells. Among phenotypic cell markers, surface membrane antigens have been extensively studied on the immunological state in pregnancy, peripheral lymphocyte subsets from pregnant women by the use of monoclonal antibodies. From gynecological and obstetrical patients management perspective, a role of cell sorting technology in flow cytometry is emerging as a tool for diagnosis of cancer (DNA abnormalities and cell cycle analysis) multiparameter analysis in quantitation (DNA base pairs, RNA and protein), surface markers for immunological state in pregnancy (membrane antigen and monoclonal antibodies), prognosis (adverse impact of aneuploidy and high S percentage using BrdU with monoclonal antibody) and targeting cytotoxicity to steroid responding tumor cells (estrogen receptor and site-directed chemotherapy).

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

I Nishiya. 1988. [Cell sorting in flow cytometry].. https://pubmed.ncbi.nlm.nih.gov/3251962/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Maternal age as a driver of genome instability: mechanisms linking aneuploidy, mutagenesis and mitochondrial dysfunction.

Advanced maternal age is a well-established risk factor for adverse reproductive outcomes due to increased rates of aneuploidy. However, emerging evidence indicates that the genetic consequences of maternal aging extend well beyond chromosome mis-segregation. Aging oocytes acquire a broad spectrum of genetic abnormalities, including maternally derived nuclear de novo mutations (DNMs) and mitochondrial DNA mutations, together with epigenetic dysregulation of DNA methylation and post-translational modification levels. These changes reflect the unique biology of the female germline in which oocytes remain arrested in meiotic prophase I for decades. Age-related deterioration of key processes, such as erosion of cohesion complexes, altered meiotic recombination, and weakened spindle assembly checkpoint surveillance collectively destabilize meiotic chromosome architecture, directly driving chromosome mis-segregation. At the same time, accumulation of endogenous DNA damage and declining DNA damage and repair processes increase the chances of transmitting lesions that can be converted into sequence-level mutations during the earliest embryonic divisions, when genome maintenance relies exclusively on maternal factors. High-resolution sequencing studies further demonstrate that maternal aging is associated with increased DNMs burden in both nuclear and mitochondrial DNA. Together, these findings support a model in which maternal aging is a driver of genome-wide instability that links aneuploidy and mutagenesis through shared defects in meiotic surveillance, declining DNA repair efficiency, and mitochondrial function. This framework positions delayed childbearing as a multifaceted genetic risk factor that extend beyond aneuploidy to include mutations and other genomic alterations that can impact intergenerational genetic risk.

Aneuploidy

Modeling and targeting general and chromosome-specific aneuploidy in cancer.

Throughout the last century, aneuploidy has been cemented as a hallmark of cancer. Although the association of aneuploidy with tumorigenesis has been well established, the role of these genetic imbalances in tumor formation has only recently begun to be elucidated. Advancements in genomics have revealed the complexity and context dependence of the effect of aneuploidy on cancer growth, while developments in genetic editing have allowed for proper modeling of specific aneuploidies. In this review, we discuss the key factors to consider when studying the role of aneuploidy in cancer and the tools that are available to do so. We then highlight recent studies that establish phenotypic contributions of aneuploidy to tumorigenicity. In particular, we highlight how general aneuploidy and chromosomal instability affect the tumor microenvironment and how specific chromosomal alterations, including the loss of chromosome 9p and the gain of chromosomes 8q and 1q, influence tumor behavior and therapeutic responses. Finally, we emphasize the potential of targeting aneuploidy-induced vulnerabilities to improve cancer treatment outcomes.

Aneuploidy

DNA flow cytometry of epithelioid sarcoma.

DNA ploidy of paraffin-embedded tissue from 11 patients with epithelioid sarcoma and 20 control specimens (granuloma annulare and sarcoid) was studied. DNA aneuploidy was found in 64% of the epithelioid sarcomas and in none of the control samples. Aneuploidy did not correlate with necrosis, vascular invasion, or mitotic rate. There was also no association of aneuploidy with adverse outcome.

Aneuploidy